Caxton Associates LP Buys 1,166 Shares of Cencora, Inc. (NYSE:COR)

Caxton Associates LP lifted its stake in shares of Cencora, Inc. (NYSE:COR) by 27.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,491 shares of the company’s stock after purchasing an additional 1,166 shares during the quarter. Caxton Associates LP’s holdings in Cencora were worth $1,234,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in COR. Franklin Resources Inc. lifted its stake in shares of Cencora by 20.4% in the 3rd quarter. Franklin Resources Inc. now owns 207,131 shares of the company’s stock valued at $46,564,000 after acquiring an additional 35,024 shares during the last quarter. Retirement Systems of Alabama increased its holdings in Cencora by 4.0% in the 3rd quarter. Retirement Systems of Alabama now owns 37,987 shares of the company’s stock worth $8,550,000 after purchasing an additional 1,470 shares in the last quarter. Principal Financial Group Inc. raised its position in Cencora by 6.9% in the third quarter. Principal Financial Group Inc. now owns 306,726 shares of the company’s stock valued at $69,038,000 after purchasing an additional 19,831 shares during the last quarter. Nordea Investment Management AB boosted its stake in shares of Cencora by 40.2% during the fourth quarter. Nordea Investment Management AB now owns 1,077,272 shares of the company’s stock valued at $243,173,000 after purchasing an additional 308,773 shares in the last quarter. Finally, Pensionfund Sabic grew its holdings in shares of Cencora by 38.5% during the fourth quarter. Pensionfund Sabic now owns 7,200 shares of the company’s stock worth $1,618,000 after purchasing an additional 2,000 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Trading Down 0.1 %

Shares of COR stock opened at $291.80 on Tuesday. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $296.65. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. The stock has a 50 day simple moving average of $273.47 and a two-hundred day simple moving average of $252.02. The company has a market cap of $56.58 billion, a P/E ratio of 41.51, a PEG ratio of 1.31 and a beta of 0.60.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Research analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were paid a $0.55 dividend. The ex-dividend date was Friday, February 14th. This represents a $2.20 annualized dividend and a dividend yield of 0.75%. Cencora’s dividend payout ratio is presently 31.29%.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on COR shares. Wells Fargo & Company lifted their target price on shares of Cencora from $251.00 to $274.00 and gave the stock an “equal weight” rating in a research report on Friday, March 14th. UBS Group lifted their price target on shares of Cencora from $298.00 to $335.00 and gave the stock a “buy” rating in a report on Tuesday, April 29th. Bank of America increased their price objective on Cencora from $270.00 to $285.00 and gave the company a “neutral” rating in a report on Friday, April 11th. Evercore ISI lifted their target price on Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a report on Thursday, February 6th. Finally, Morgan Stanley set a $288.00 price target on Cencora in a research note on Tuesday, April 15th. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $290.00.

Insider Activity at Cencora

In related news, CEO Robert P. Mauch sold 4,969 shares of the stock in a transaction on Monday, April 21st. The stock was sold at an average price of $289.33, for a total value of $1,437,680.77. Following the transaction, the chief executive officer now directly owns 47,582 shares in the company, valued at $13,766,900.06. This trade represents a 9.46 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Silvana Battaglia sold 5,000 shares of the business’s stock in a transaction on Friday, February 21st. The shares were sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the sale, the executive vice president now owns 15,374 shares of the company’s stock, valued at $3,724,197.76. This trade represents a 24.54 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 50,223 shares of company stock valued at $13,580,967 in the last three months. Corporate insiders own 10.80% of the company’s stock.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.